ULBI vs. STEM, GWH, NVX, ELVA, CBAT, FLUX, DFLI, SES, COMM, and CANG
Should you be buying Ultralife stock or one of its competitors? The main competitors of Ultralife include Stem (STEM), ESS Tech (GWH), NOVONIX (NVX), Electrovaya (ELVA), CBAK Energy Technology (CBAT), Flux Power (FLUX), Dragonfly Energy (DFLI), SES AI (SES), CommScope (COMM), and Cango (CANG). These companies are all part of the "computer and technology" sector.
Ultralife (NASDAQ:ULBI) and Stem (NYSE:STEM) are both small-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.
In the previous week, Ultralife had 1 more articles in the media than Stem. MarketBeat recorded 4 mentions for Ultralife and 3 mentions for Stem. Ultralife's average media sentiment score of 0.85 beat Stem's score of 0.28 indicating that Ultralife is being referred to more favorably in the media.
Ultralife has higher earnings, but lower revenue than Stem. Stem is trading at a lower price-to-earnings ratio than Ultralife, indicating that it is currently the more affordable of the two stocks.
30.7% of Ultralife shares are held by institutional investors. Comparatively, 61.6% of Stem shares are held by institutional investors. 42.7% of Ultralife shares are held by insiders. Comparatively, 10.2% of Stem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ultralife received 233 more outperform votes than Stem when rated by MarketBeat users. Likewise, 71.51% of users gave Ultralife an outperform vote while only 41.18% of users gave Stem an outperform vote.
Ultralife currently has a consensus target price of $13.00, indicating a potential upside of 11.88%. Stem has a consensus target price of $4.77, indicating a potential upside of 262.97%. Given Stem's higher probable upside, analysts plainly believe Stem is more favorable than Ultralife.
Ultralife has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Stem has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Ultralife has a net margin of 6.19% compared to Stem's net margin of -40.03%. Ultralife's return on equity of 10.31% beat Stem's return on equity.
Summary
Ultralife beats Stem on 13 of the 18 factors compared between the two stocks.
Get Ultralife News Delivered to You Automatically
Sign up to receive the latest news and ratings for ULBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ULBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultralife Competitors List
Related Companies and Tools
